Free clinical cognitive assessment Topical Map Generator
Use this free clinical cognitive assessment for Alzheimer's topical map generator to plan topic clusters, pillar pages, article ideas, content briefs, AI prompts, and publishing order for SEO.
Built for SEOs, agencies, bloggers, and content teams that need a practical content plan for Google rankings, AI Overview eligibility, and LLM citation.
1. Clinical and Cognitive Assessment
Covers the bedside and clinic-based evaluation: history, cognitive screening, structured neuropsychological testing, informant tools and functional assessment. This is the first decision point and determines who needs imaging or biomarkers.
Comprehensive Clinical and Cognitive Assessment for Suspected Alzheimer's Disease
A definitive guide to taking a dementia-focused history, choosing and interpreting cognitive screens (MMSE, MoCA), designing neuropsychological batteries, and using informant and functional scales to stage cognitive impairment. Clinicians gain clear protocols, thresholds for escalation, and structured differential-diagnosis steps to decide when imaging or biomarkers are indicated.
MMSE vs MoCA: Choosing and Interpreting Cognitive Screening Tests
Side-by-side comparison of MMSE and MoCA including psychometrics, cutoffs by education and age, administration tips, and how scores map to clinical action. Useful for primary care and neurology clinicians deciding which screen to use.
Neuropsychological Testing for Early Alzheimer's: Batteries, Domains, and Interpretation
Explains which neuropsych tests detect the amnestic profile of Alzheimer's versus other patterns, how to interpret domain-specific deficits, and how results affect diagnosis and treatment planning.
Functional and Behavioral Assessments: ADL, IADL, CDR, and NPI Explained
Summarizes the major scales used to assess daily function and neuropsychiatric symptoms, how to administer them, scoring interpretation, and their role in staging and care planning.
Primary Care Cognitive Assessment Checklist: When to Order Tests or Refer
Practical checklist for primary care clinicians: history prompts, red flags, initial labs, cognitive screens, and clear referral thresholds for imaging, CSF testing, or specialist evaluation.
Common Mimics of Alzheimer's: Depression, Medication Effects, and Other Causes
Describes conditions that mimic AD, clinical clues to differentiate them, and recommended targeted tests to rule out reversible causes.
2. Structural Neuroimaging (MRI & CT)
Focuses on structural brain imaging: MRI sequences, CT use, visual ratings and automated volumetry, and how structural findings contribute to diagnosis and differential (including vascular contributions).
MRI and CT in Alzheimer's Diagnosis: Protocols, Interpretation, and Reporting
Authoritative guidance on when and how to use MRI and CT in suspected Alzheimer's disease, including recommended sequences and protocols, visual rating scales for medial temporal atrophy and white matter disease, automated volumetric tools, and standardized reporting templates that aid clinical decision-making.
MRI Protocol for Dementia: Sequences, Parameters, and Rationale
Detailed, implementable MRI protocol for dementia workup (T1, T2, FLAIR, SWI, DWI, volumetric T1) with rationale for each sequence and acquisition tips for consistent assessment.
Assessing Hippocampal Atrophy and Cortical Thickness: Visual Scales and Automated Tools
Explains medial temporal atrophy scales, how to score them, strengths and limits of automated hippocampal volumetry and cortical thickness analysis, and how to incorporate results into diagnostic reports.
CT for Cognitive Decline: Appropriate Use, Findings, and Limitations
When CT is acceptable versus when MRI is preferred, what key findings on CT (atrophy, infarcts, hemorrhage, hydrocephalus) can indicate, and limitations to be aware of.
Vascular Brain Injury, White Matter Hyperintensities, and Mixed Dementia
Describes imaging features of small vessel disease, leukoaraiosis, lacunes and how vascular pathology interacts with Alzheimer's pathology to affect diagnosis and management.
Structured Reporting Templates for Structural Imaging in Dementia
Provides ready-to-use radiology reporting templates and example language that communicates degree of atrophy, vascular burden, and recommended next steps to referring clinicians.
3. Molecular Imaging (PET & SPECT)
Covers molecular imaging modalities — amyloid and tau PET, FDG-PET metabolic imaging, and SPECT — including tracers, interpretation, indications, and how these tests change diagnostic certainty and management.
PET and SPECT Imaging in Alzheimer's Disease: Amyloid, Tau, and Metabolic Scans
Comprehensive guide to molecular imaging for Alzheimer's including approved amyloid tracers, tau PET developments, FDG-PET metabolic patterns, appropriate-use criteria, interpretation pitfalls, and how PET results should be integrated into clinical decisions and trial enrollment.
Amyloid PET: Indications, Tracers, and How to Interpret Results
Walks through FDA/appropriate-use criteria, commonly used tracers (florbetapir, florbetaben, flutemetamol), positive vs negative scans, false positives, and how amyloid PET affects diagnostic certainty and counseling.
Tau PET Imaging: Tracers, Clinical Utility, and Research Applications
Explains tau PET biology, available tracers, how tau distribution correlates with clinical stage, and current evidence for clinical versus research use.
FDG-PET for Dementia: Characteristic Patterns and Differential Diagnosis
Describes typical hypometabolic patterns in Alzheimer's versus frontotemporal, Lewy body, and vascular dementias, plus interpretation tips and limitations.
Choosing the Right Molecular Scan: Amyloid vs Tau vs FDG — A Clinician's Guide
Decision guide with clinical scenarios showing which molecular test is most informative given stage, differential diagnosis, and trial eligibility.
Cost, Access, and Reimbursement for PET Imaging in Alzheimer's Diagnosis
Overview of typical costs, insurance coverage patterns, geographic access issues, and strategies to obtain testing for patients and researchers.
4. Fluid Biomarkers (CSF & Blood)
Explains cerebrospinal fluid and emerging blood-based biomarkers: lab techniques, interpretation, practicalities of lumbar puncture, and how biomarkers track pathophysiology and progression.
Cerebrospinal Fluid and Blood Biomarkers for Alzheimer's: Practical Use and Interpretation
Authoritative coverage of CSF biomarkers (Aβ42/40, t-tau, p-tau), blood-based assays (plasma p-tau, Aβ42/40, NfL), pre-analytical considerations, assay selection and interpretation, and real-world guidance on when to order and how results change care.
Lumbar Puncture for CSF Biomarkers: Procedure, Risks, and Patient Counseling
Stepwise lumbar puncture guidance, informed consent language, how to minimize complications, and practical counseling points patients commonly ask.
Interpreting CSF Biomarker Results: Aβ42, Aβ42/40, t-tau and p-tau
Explains typical CSF patterns in Alzheimer's versus other neurodegenerative and inflammatory conditions, provides examples of cutoff values and lab variability, and shows clinical decision pathways based on results.
Blood-based Biomarkers for Alzheimer's: Plasma p-tau, Aβ42/40, and NfL — Evidence and Clinical Use
Summarizes validation studies for plasma p-tau and other assays, their accuracy compared with CSF and PET, current clinical roles, and how they can expand access to biomarker testing.
Laboratory Standardization and How to Choose a Biomarker Assay
Guidance on selecting accredited labs/assays, understanding pre-analytical variables, and interpreting lab reports with knowledge of assay-specific cutoffs.
Using Biomarkers to Monitor Disease Course and for Clinical Trials
Explains how biomarkers change over disease course, their role as endpoints in trials, and practical considerations when using serial measures clinically or in research.
5. Genetic Testing and Risk Stratification
Addresses genetic contributors to Alzheimer's risk — ApoE, early-onset familial genes, testing indications, counseling, and implications for families and clinical care.
Genetic Testing and Risk Assessment in Alzheimer's Disease: Practical Guidance and Counseling
Comprehensive discussion of ApoE genotyping, indications for testing for deterministic genes (APP, PSEN1/2), the process and ethics of genetic counseling, and how genetic results influence risk communication, testing strategies, and eligibility for targeted trials.
ApoE Genotyping: What It Means for Risk, Counseling, and Clinical Decisions
Explains ApoE alleles, how genotype affects relative risk, practice recommendations on offering testing, and counseling points for patients and families.
When to Test for Familial Alzheimer's Genes: Criteria, Process, and Referral
Clear criteria for referral for molecular genetic testing for early-onset familial AD, how testing is performed, and how results are used clinically and for family planning.
Genetic Counseling for Alzheimer's: Best Practices and Ethical Considerations
Practical guidance for genetic counselors and clinicians on pre- and post-test counseling, managing uncertainty, and addressing family communication and psychosocial impacts.
Interpreting Direct-to-Consumer Alzheimer's Risk Reports
Explains limitations of DTC tests, common misinterpretations, and guidance clinicians can use to advise patients who present with DTC results.
6. Diagnostic Integration, Guidelines, and Care Pathways
Brings together tests and findings into stepwise diagnostic algorithms, guideline-aligned pathways, reporting standards, ethical and access issues, and how to use results for management and trial enrollment.
Integrating Tests into a Practical Alzheimer's Diagnostic Pathway: Guidelines, Algorithms, and Best Practices
An end-to-end, guideline-aligned roadmap for clinicians that specifies stepwise evaluation from primary care to specialist, how to sequence cognitive tests, imaging, and biomarkers, criteria for trial and treatment eligibility, documentation templates, and equity and access considerations. The pillar includes reproducible algorithms, flowcharts, and communication scripts to standardize high-quality diagnostic care.
Step-by-Step Diagnostic Algorithm for Primary Care: When and What to Order
Concise, actionable algorithm for primary care showing which tests to order at each step, red flags requiring urgent referral, and sample order sets and lab panels.
Referral Criteria and Triage for Memory Clinics and Neurology
Defines clear referral thresholds, prioritization for resource-limited settings, and information to include with referrals to streamline evaluation.
How to Communicate Biomarker Results and an Alzheimer's Diagnosis to Patients and Families
Provides empathetic, evidence-based scripts and documentation templates tailored to different stages (MCI with positive biomarkers, biomarker-negative concerns) and guidance on counseling about prognosis and next steps.
Using Diagnostic Tests for Trial Enrollment and Disease-Modifying Therapy Decisions
Explains typical biomarker and imaging eligibility criteria for trials and for emerging disease-modifying treatments, plus how to prepare documentation and consent for participation.
Insurance, Cost, and Equity in Access to Alzheimer's Diagnostic Testing
Discusses payer landscapes, strategies to reduce disparities in access to imaging and biomarker testing, and policy considerations to improve equitable diagnosis.
Content strategy and topical authority plan for Alzheimer's Diagnostic Pathway: Tests and Imaging
The recommended SEO content strategy for Alzheimer's Diagnostic Pathway: Tests and Imaging is the hub-and-spoke topical map model: one comprehensive pillar page on Alzheimer's Diagnostic Pathway: Tests and Imaging, supported by 29 cluster articles each targeting a specific sub-topic. This gives Google the complete hub-and-spoke coverage it needs to rank your site as a topical authority on Alzheimer's Diagnostic Pathway: Tests and Imaging.
35
Articles in plan
6
Content groups
22
High-priority articles
~6 months
Est. time to authority
Search intent coverage across Alzheimer's Diagnostic Pathway: Tests and Imaging
This topical map covers the full intent mix needed to build authority, not just one article type.
Entities and concepts to cover in Alzheimer's Diagnostic Pathway: Tests and Imaging
Publishing order
Start with the pillar page, then publish the 22 high-priority articles first to establish coverage around clinical cognitive assessment for Alzheimer's faster.
Estimated time to authority: ~6 months